Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. However, the necessity of Massive Bio increases everyday to streamline disparate clinical and genomic information and disparate stakeholders. Precision oncology needs a translator and accelerator more than ever to be mainstream. Massive Bio put precision oncology to “work” — organizes and harmonizes disparate knowledge into clinical utility. In any case, I have summarized our key take-aways from the conference in regards to our space, digital health and AI and overall healthcare. Hope you will find it as an enjoyable read and I am always happy to have a dialogue and attack healthcare issues with like minded people together.
The American Turkish Society is pleased to announce the sixth class of "Young Society Leaders," a group of 25 accomplished professionals with a demonstrated record of leadership ability and commitment to serve the U.S.-Turkish community at large.
Massive Bio is in the holiday spirit this year, so we are starting our Black Friday deal early and ending it late! Give thanks to those you love by giving them the gift of Massive Bio to find the best cancer treatment for your loved one or for yourself.
Much has been said and written about the lack of women in the tech sector, be it as investors (or associates), founders, or in management positions at major companies. Is the problem the old boys network – or that success in technology is seen as a young man’s game? In this series, we speak with some of the top women in tech in New York as they discuss the challenges they face, the perceptions that need to be changed and the work that’s being done – or not – to help to promote women in tech.
Today we speak with Dr. Selin Kurnaz, CEO and cofounder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Pharmaceutical and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoke extensively about life sciences in tech and how to deliver information in creative ways.
On June 27, 2017, a member of the Massive Bio Team, Belisario A. Arango, M.D., took part of the Cancer Moonshot Project and the Biden Cancer Initiative Meeting in Washington, D.C. The meeting was hosted by Kim Thiboldeaux, CEO of Cancer Support Community and a member of the Board of Directors of the Biden Cancer Initiative. The purpose of this meeting was to update the cancer community on the accomplishments over the past year, since the announcement of the Moonshot challenge, and to discuss the goals that are expected to be reached over the next 4 years.